Andrea Pellacani

2.9k total citations · 1 hit paper
48 papers, 2.1k citations indexed

About

Andrea Pellacani is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Andrea Pellacani has authored 48 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 12 papers in Surgery and 11 papers in Oncology. Recurrent topics in Andrea Pellacani's work include Orthopaedic implants and arthroplasty (6 papers), Heme Oxygenase-1 and Carbon Monoxide (5 papers) and HER2/EGFR in Cancer Research (4 papers). Andrea Pellacani is often cited by papers focused on Orthopaedic implants and arthroplasty (6 papers), Heme Oxygenase-1 and Carbon Monoxide (5 papers) and HER2/EGFR in Cancer Research (4 papers). Andrea Pellacani collaborates with scholars based in Italy, United States and Spain. Andrea Pellacani's co-authors include Mark A. Perrella, Massimo Cugno, Marco Cicardi, Juerg Nussberger, C Amstutz, Philippe Wiesel, Shaw‐Fang Yet, Lauren C. Foster, Jürg Nussberger and Michael T. Chin and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Circulation.

In The Last Decade

Andrea Pellacani

45 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma bradykinin in angio-oedema

1998 553 citations Juerg Nussberger, Massimo Cugno et al. The Lancet profile →

Peers

Countries citing papers authored by Andrea Pellacani

Since Specialization

Citations

This map shows the geographic impact of Andrea Pellacani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Pellacani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Pellacani more than expected).

Fields of papers citing papers by Andrea Pellacani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Pellacani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Pellacani. The network helps show where Andrea Pellacani may publish in the future.

Co-authorship network of co-authors of Andrea Pellacani

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Pellacani. A scholar is included among the top collaborators of Andrea Pellacani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Pellacani. Andrea Pellacani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	489P MEN1611 in combination with cetuximab: Targeting PIK3CA mutations in RAS-wild-type patient-derived colorectal cancer xenografts 2021 ·Annals of Oncology ·(unknown), G. Merlino, Mario Bigioni, Patrizia Tunici, Francesca Cottino, Eugenia R. Zanella, Valentina Vurchio, Andrea Bertotti, Livio Trusolino, Dirk Laurent, Andrea Pellacani, Monica Binaschi	2
2	266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01) 2021 ·Annals of Oncology ·Martine Piccart, Manuel Ruíz Borrego, H-T. Arkenau, Santiago Escrivá-de-Romaní, Sacha J. Howell, Audrey Hennequin, (unknown), (unknown), Matteo Simonelli, Michela Palleschi, François P. Duhoux, (unknown), Giuseppe Curigliano, Simon Waters, Philippe Aftimos, Hans Wildiers, Diégo Tosi, (unknown), Andrea Pellacani, Dirk Laurent	4
3	P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens 2020 ·Annals of Oncology ·Josep Tabernero, Élena Elez, François Ghiringhelli, Gunnar Folprecht, Giuseppe Curigliano, Salvatore Siena, Chiara Cremolini, Alberto F. Sobrero, Michał Kwiatek, Susana Roselló, Daniel H. Ahn, Cornelis J.A. Punt, Laurent Dembélé, Marianna Ferrara, Andrea Pellacani, Angela Capriati	5
4	347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC) 2020 ·Annals of Oncology ·Martine Piccart, Manuel Ruíz Borrego, François P. Duhoux, H-T. Arkenau, (unknown), Hans Wildiers, Mario Campone, Diégo Tosi, Javier García-Corbacho, Begoña Jiménez, (unknown), Andrew Wardley, Pierfrancesco Tassone, Valentina Boni, Yolanda Jerez, Philippe Aftimos, Audrey Hennequin, (unknown), Andrea Pellacani, Dirk Laurent	2
5	Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus 2015 ·Diabetologia ·(unknown), David Preiss, Dirk Blom, C. Stephen Djedjos, Mary Elliott, Andrea Pellacani, Scott M. Wasserman, Michael J. Koren, R Holman	6
6	Efficacy of one year of treatment with the PCSK9 inhibitor evolocumab (AMG 145) in 4,802 subjects with or without type 2 diabetes 2015 ·Diabetologia ·David Preiss, Naveed Sattar, J Robinson, C. Stephen Djedjos, Mary Elliott, Andrea Pellacani, Scott M. Wasserman, Dirk Blom, Frederick J. Raal	0
7	Molecular targeting of the GK-GKRP pathway in diabetes 2014 ·Expert Opinion on Therapeutic Targets ·Clarence Hale, David J. Lloyd, Andrea Pellacani, Murielle M. Véniant	16
8	Is wear debris responsible for failure in alumina-on-alumina implants? 2009 ·Acta Orthopaedica ·L. Savarino, Nicola Baldini, G. Ciapetti, Andrea Pellacani, Armando Giunti	15
9	In vitro blockade of receptor activator of nuclear factor‐κB ligand prevents osteoclastogenesis induced by neuroblastoma cells 2004 ·International Journal of Cancer ·Donatella Granchi, (unknown), (unknown), Sofia Avnet, S. Capaccioli, Laura Papucci, Martino Donnini, Andrea Pellacani, Maria Luisa Brandi, Armando Giunti, Nicola Baldini	42
10	Xanthoma of Bone: First Sign of Hyperlipidemia Type IIB 2003 ·Clinical Orthopaedics and Related Research ·Dante Dallari, Alessandro Marinelli, Andrea Pellacani, (unknown), (unknown), Franco Bertoni, Armando Giunti	16
11	Down-regulation of High Mobility Group-I(Y) Protein Contributes to the Inhibition of Nitric-oxide Synthase 2 by Transforming Growth Factor-β1 2001 ·Journal of Biological Chemistry ·Andrea Pellacani, Philippe Wiesel, (unknown), (unknown), Mark W. Feinberg, Michael T. Chin, Raymond Reeves, Mark A. Perrella	29
12	ESE-1 Is a Novel Transcriptional Mediator of Inflammation That Interacts with NF-κB to Regulate the Inducible Nitric-oxide Synthase Gene 2001 ·Journal of Biological Chemistry ·Susan A. Rudders, John Gaspar, (unknown), Carole Voland, Franck Grall, Anand Patel, Andrea Pellacani, Mark A. Perrella, Towia A. Libermann, Peter Oettgen	84
13	Thioredoxin Facilitates the Induction of Heme Oxygenase-1 in Response to Inflammatory Mediators 2000 ·Journal of Biological Chemistry ·Philippe Wiesel, Lauren C. Foster, Andrea Pellacani, Matthew D. Layne, Chung-Ming Hsieh, Gordon S. Huggins, Phyllis R. Strauss, Shaw‐Fang Yet, Mark A. Perrella	107
14	Role of activating protein‐1 and high mobility group‐I(Y) protein in the induction of CD44 gene expression by interleukin‐1β in vascular smooth muscle cells 2000 ·The FASEB Journal ·Lauren C. Foster, Philippe Wiesel, Gordon S. Huggins, (unknown), Michael T. Chin, Andrea Pellacani, Mark A. Perrella	45
15	Induction of High Mobility Group-I(Y) Protein by Endotoxin and Interleukin-1β in Vascular Smooth Muscle Cells 1999 ·Journal of Biological Chemistry ·Andrea Pellacani, Michael T. Chin, Philippe Wiesel, Maureen Ibanez, Anand Patel, Shaw‐Fang Yet, Chung-Ming Hsieh, Joseph Paulauskis, Raymond Reeves, Mu-En Lee, Mark A. Perrella	36
16	Induction of High Mobility Group I Architectural Transcription Factors in Proliferating Vascular Smooth Muscle in vivo and in vitro 1999 ·Journal of Molecular and Cellular Cardiology ·Michael T. Chin, Andrea Pellacani, (unknown), Sharon Lin, Mukesh K. Jain, Anand Patel, Gordon S. Huggins, Raymond Reeves, Mark A. Perrella, M E Lee	15
17	High Mobility Group-I(Y) Protein Facilitates Nuclear Factor-κB Binding and Transactivation of the Inducible Nitric-oxide Synthase Promoter/Enhancer 1999 ·Journal of Biological Chemistry ·Mark A. Perrella, Andrea Pellacani, Philippe Wiesel, Michael T. Chin, Lauren C. Foster, Maureen Ibanez, Chung-Ming Hsieh, Raymond Reeves, Shaw‐Fang Yet, Mu-En Lee	53
18	Plasma bradykinin in angio-oedema breakdown → 1998 ·The Lancet ·Juerg Nussberger, Massimo Cugno, C Amstutz, Marco Cicardi, Andrea Pellacani, (unknown)	553
19	Enhancement of Serum-response Factor-dependent Transcription and DNA Binding by the Architectural Transcription Factor HMG-I(Y) 1998 ·Journal of Biological Chemistry ·Michael T. Chin, Andrea Pellacani, Hong Wang, Sharon Lin, Mukesh K. Jain, Mark A. Perrella, Mu-En Lee	65
20	Antagonizing and Measurement: Approaches to Understanding of Hemodynamic Effects of Kinins 1992 ·Journal of Cardiovascular Pharmacology ·Andrea Pellacani, H R Brunner, Jürg Nussberger	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact